Homozygous 2bp Deletion in the Human Factor VII Gene: A Non-Lethal Mutation that Is Associated with a Complete Absence of Circulating Factor VII

Summary

We report the case of a 5-year-old boy with severe factor VII deficiency. The affected child presented at the age of 8 months and again at 18 months with bleeding from the gastrointestinal tract but the diagnosis of factor VII deficiency was not made until the age of 3 years. He was treated with fresh frozen plasma and subsequently factor VII concentrates and to date remains well. To identify the causative mutation, the factor VII gene was screened by SSCP and direct sequence analysis. A single homozygous 2bp deletion (-CT) mutation was identified in exon 1a removing nucleotides 27/28 (codons 52/53). Both parents, who were first cousins, were heterozygous for the mutation. The mutation located in the prepropeptide of factor VII, results in a complete absence of factor VII in plasma. This case indicates that a complete absence of plasma factor VII is not necessarily a lethal condition.

Key words

FVII - mutation - deletion

• References

• 1 Bajaj SP, Rapaport SI, Brown SF. Isolation and characterization of human factor VII. Activation of factor VII by factor Xa. J Biol Chem 1981; 256: 253-9.
• 2 Hagen FS, Gray CL, O’Hara P, Grant FJ, Saari GC, Woodbury RG. et al. Characterization of a cDNA coding for human factor VII. Proc Natl Acad Sci USA 1986; 83: 2412-6.
• 3 O’Hara PJ, Grant FJ, Haldeman BA, Gray CL, Insley MY, Hagen FS. et al. Nucleotide sequence of the gene coding for human factor VII, a vitamin K-dependent protein participating in blood coagulation. Proc Natl Acad Sci USA 1987; 84: 5158-62.
• 4 Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66: 67-79.
• 5 Camerer E, Kolstá AB, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996; 81: 1-41.
• 6 Triplett DA, Brandt JT, Batard MA, Dixon JL, Fair DS. Hereditary factor VII deficiency: heterogeneity defined by combined functional and immunochemical analysis. Blood 1985; 66: 1284-7.
• 7 Peyvandi F, Mannucci PF, Asti D, Abdoullahi M, Di Rocco N, Sharifian R. Clinical manifestations in 28 Italian and Iranian Patients with Severe Factor VII Deficiency. Haemophilia 1997; 03: 242-6.
• 8 McVey JH, Boswell EJ, Takamiya O, Tamagnini G, Valente V, Fidalgo T. et al. Exclusion of the First EGF Domain of Factor VII by a Splice Site Mutation Causes Lethal Factor VII Deficiency. Blood 1998; 92: 920-6.
• 9 Poggio M, Tripodi A, Mariani G, Mannucci PM. Factor VII Clotting Assays: Influence of Different Thromboplastins and Factor VII Deficient plasmas. Thromb Haemost 1991; 65: 160-4.
• 10 Coppola R, Tombesi S, Valentini F, Alborali S, Albertini A, Mannucci PM. Enzyme-linked immunosorbent assay of human factor VII based upon a monoclonal antibody that recognizes the native conformation of the protein. Thromb Res 1992; 68: 283-93.
• 11 Berkner K, Busby S, Davie E, Hart C, Insley M, Kisiel W. et al. Isolation and expression of cDNAs encoding human factor VII. Cold Spring Harb Symp Quant Biol 1986; 51 Pt 1: 531-41.
• 12 Rosen ED, Chan JC, Idusogie E, Clotman F, Vlasuk G, Luther T. et al. Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature 1997; 390: 290-4.
• 13 Linton MF, Pierotti V, Young SG. Reading-frame restoration with an apolipoprotein B gene frameshift mutation. Proc Natl Acad Sci USA 1992; 89: 11431-5.
• 14 Young M, Inaba H, Hoyer LW, Higuchi M, Kazazian Jr HH, Antonarakis SE. Partial correction of a severe molecular defect in hemophilia A, because of errors during expression of the factor VIII gene. Am J Hum Genet 1997; 60: 565-73.